Selective inhibitors for BET-BD1 and BET-BD2 have been shown to represent more effective therapeutic strategies for cancer and inflammatory diseases, respectively, as the toxicity linked to the inhibition of a single BET-BD appears to be substantially lower than that associated with pan-BET-BD inhibition [153]. This evidence concerns the gene DNER and cancer.